{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:16:53Z","timestamp":1783131413147,"version":"3.54.6"},"reference-count":153,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon 2020","doi-asserted-by":"publisher","award":["963845"],"award-info":[{"award-number":["963845"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.tox.2025.154162","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T02:50:29Z","timestamp":1745290229000},"page":"154162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["An adverse outcome pathway for DNA adduct formation leading to kidney failure"],"prefix":"10.1016","volume":"515","author":[{"given":"D.A.","family":"Barnes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.A.","family":"Redegeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Masereeuw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.tox.2025.154162_bib1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.semnephrol.2018.12.004","article-title":"Cellular and molecular mechanisms of kidney toxicity","volume":"39","author":"Barnett","year":"2019","journal-title":"Semin Nephrol."},{"issue":"7","key":"10.1016\/j.tox.2025.154162_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071572","article-title":"Mechanisms of cisplatin-induced acute kidney injury: pathological mechanisms, pharmacological interventions, and genetic mitigations","volume":"13","author":"McSweeney","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.tox.2025.154162_bib3","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s00204-023-03637-7","article-title":"Development of an adverse outcome pathway network for nephrotoxicity","volume":"98","author":"Barnes","year":"2024","journal-title":"Arch. Toxicol."},{"issue":"3","key":"10.1016\/j.tox.2025.154162_bib4","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/etc.34","article-title":"Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment","volume":"29","author":"Ankley","year":"2010","journal-title":"Environ. Toxicol. Chem."},{"key":"10.1016\/j.tox.2025.154162_bib5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tox.2013.08.011","article-title":"The adverse outcome pathway concept: a pragmatic tool in toxicology","volume":"312","author":"Vinken","year":"2013","journal-title":"Toxicology"},{"key":"10.1016\/j.tox.2025.154162_bib6","series-title":"Guidance Document on Developing and Assessing Adverse Outcome Pathways","author":"OECD","year":"2017"},{"issue":"19","key":"10.1016\/j.tox.2025.154162_bib7","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1039\/C8DT00838H","article-title":"The side effects of platinum-based chemotherapy drugs: a review for chemists","volume":"47","author":"Oun","year":"2018","journal-title":"Dalton Trans."},{"issue":"6","key":"10.1016\/j.tox.2025.154162_bib8","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1517\/14740338.2.6.597","article-title":"Toxicities of the platinum antineoplastic agents","volume":"2","author":"Markman","year":"2003","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.tox.2025.154162_bib9","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3389\/fphar.2018.01111","article-title":"Genetic variations and cisplatin nephrotoxicity: a systematic review","volume":"9","author":"Zazuli","year":"2018","journal-title":"Front. Pharm."},{"issue":"4","key":"10.1016\/j.tox.2025.154162_bib10","article-title":"Cisplatin-based chemotherapy of human cancers","volume":"11","author":"Brown","year":"2019","journal-title":"J. Cancer Sci. Ther."},{"issue":"6","key":"10.1016\/j.tox.2025.154162_bib11","first-page":"1310","article-title":"Clinical and pharmacological studies with cis-diamminedichloroplatinum (II)","volume":"33","author":"DeConti","year":"1973","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.tox.2025.154162_bib12","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00002820-198010000-00004","article-title":"History and development of cisplatin in the management of malignant disease","volume":"3","author":"Eustace","year":"1980","journal-title":"Cancer Nurs."},{"issue":"1","key":"10.1016\/j.tox.2025.154162_bib13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF00048279","article-title":"Advances in platinum cancer chemotherapy. Advances in the design of cisplatin analogues","volume":"7","author":"Hydes","year":"1988","journal-title":"Cancer Metastas. Rev."},{"issue":"3","key":"10.1016\/j.tox.2025.154162_bib14","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/BF00257742","article-title":"Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II","volume":"9","author":"Calvert","year":"1982","journal-title":"Cancer Chemother. Pharm."},{"issue":"10","key":"10.1016\/j.tox.2025.154162_bib15","first-page":"775","article-title":"Carboplatin-based combination chemotherapy for testicular cancer: relationship among administration dose of carboplatin, renal function and myelosuppression","volume":"41","author":"Suzuki","year":"1995","journal-title":"Hinyokika Kiyo"},{"issue":"1","key":"10.1016\/j.tox.2025.154162_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2007.02.001","article-title":"Mechanisms of resistance to cisplatin and carboplatin","volume":"63","author":"Stewart","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"2","key":"10.1016\/j.tox.2025.154162_bib17","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/sj.bjc.6690697","article-title":"Dose-related nephrotoxicity of carboplatin in children","volume":"81","author":"English","year":"1999","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.tox.2025.154162_bib18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1159\/000168163","article-title":"Carboplatin-induced acute renal failure","volume":"10","author":"Deray","year":"1990","journal-title":"Am. J. Nephrol."},{"issue":"12","key":"10.1016\/j.tox.2025.154162_bib19","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1021\/jm00210a029","article-title":"Antitumor activity of 1,2-diaminocyclohexane--platinum complexes against sarcoma-180 ascites form","volume":"21","author":"Kidani","year":"1978","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.tox.2025.154162_bib20","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/ndt\/gfp456","article-title":"Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs","volume":"25","author":"Haschke","year":"2010","journal-title":"Nephrol. Dial. Transpl."},{"issue":"6","key":"10.1016\/j.tox.2025.154162_bib21","first-page":"796","article-title":"Oxaliplatin-induced renal tubular vacuolization","volume":"48","author":"Joybari","year":"2014","journal-title":"Ann. Pharm."},{"issue":"4","key":"10.1016\/j.tox.2025.154162_bib22","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s10147-010-0050-0","article-title":"Renal tubular acidosis secondary to capecitabine, oxaliplatin, and cetuximab treatment in a patient with metastatic colon carcinoma: a case report and review of the literature","volume":"15","author":"Sonnenblick","year":"2010","journal-title":"Int. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.tox.2025.154162_bib23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11739-009-0331-7","article-title":"Oxaliplatin-induced proximal renal tubular acidosis","volume":"5","author":"Negro","year":"2010","journal-title":"Intern Emerg. Med."},{"issue":"4","key":"10.1016\/j.tox.2025.154162_bib24","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/annonc\/mdm080","article-title":"Renal tubular acidosis due to oxaliplatin","volume":"18","author":"Linch","year":"2007","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.tox.2025.154162_bib25","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.ackd.2021.08.001","article-title":"Conventional chemotherapy nephrotoxicity","volume":"28","author":"Gupta","year":"2021","journal-title":"Adv. Chronic Kidney Dis."},{"key":"10.1016\/j.tox.2025.154162_bib26","article-title":"Platinum drugs-related safety profile: the latest five-year analysis from FDA adverse event reporting system data","volume":"12","author":"Feng","year":"2022","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.tox.2025.154162_bib27","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1124\/mol.106.022624","article-title":"Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin","volume":"70","author":"Holzer","year":"2006","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.tox.2025.154162_bib28","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1124\/jpet.106.110346","article-title":"Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family)","volume":"319","author":"Yonezawa","year":"2006","journal-title":"J. Pharm. Exp. Ther."},{"issue":"3","key":"10.1016\/j.tox.2025.154162_bib29","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.yrtph.2015.04.004","article-title":"Increasing scientific confidence in adverse outcome pathways: application of tailored Bradford-Hill considerations for evaluating weight of evidence","volume":"72","author":"Becker","year":"2015","journal-title":"Regul. Toxicol. Pharm."},{"key":"10.1016\/j.tox.2025.154162_bib30","unstructured":"Lippert B. Chemistry and biochemistry of a leading anticancer drug. Verlag Helvetica Chimica Acta, Z\u00fcrich. 1999."},{"issue":"11","key":"10.1016\/j.tox.2025.154162_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081162","article-title":"Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions","volume":"8","author":"Marullo","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.tox.2025.154162_bib32","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s00204-015-1633-3","article-title":"DNA damage response in cisplatin-induced nephrotoxicity","volume":"89","author":"Zhu","year":"2015","journal-title":"Arch. Toxicol."},{"issue":"1","key":"10.1016\/j.tox.2025.154162_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","article-title":"Molecular mechanisms of resistance and toxicity associated with platinating agents","volume":"33","author":"Rabik","year":"2007","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.tox.2025.154162_bib34","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0079-6603(01)67026-0","article-title":"Cisplatin: from DNA damage to cancer chemotherapy","volume":"67","author":"Cohen","year":"2001","journal-title":"Prog. Nucleic Acid. Res. Mol. Biol."},{"key":"10.1016\/j.tox.2025.154162_bib35","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jab.2015.03.003","article-title":"Coordination compounds in cancer: past, present and perspectives.","author":"Trudu","year":"2015","journal-title":"J. Appl. Biomed."},{"issue":"18","key":"10.1016\/j.tox.2025.154162_bib36","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1039\/c0dt01758b","article-title":"Stability of carboplatin and oxaliplatin in their infusion solutions is due to self-association","volume":"40","author":"Di Pasqua","year":"2011","journal-title":"Dalton Trans."},{"issue":"1-4","key":"10.1016\/j.tox.2025.154162_bib37","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0162-0134(99)00180-4","article-title":"Rates of platination of -AG- and -GA- containing double-stranded oligonucleotides: effect of chloride concentration","volume":"79","author":"Davies","year":"2000","journal-title":"J. Inorg. Biochem."},{"issue":"38","key":"10.1016\/j.tox.2025.154162_bib38","doi-asserted-by":"crossref","first-page":"9378","DOI":"10.1021\/ja0023938","article-title":"Hydrolysis theory for cisplatin and its analogues based on density functional studies","volume":"123","author":"Zhang","year":"2001","journal-title":"J. Am. Chem. Soc."},{"issue":"3","key":"10.1016\/j.tox.2025.154162_bib39","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1021\/bi00324a025","article-title":"Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation","volume":"24","author":"Fichtinger-Schepman","year":"1985","journal-title":"Biochemistry"},{"issue":"5","key":"10.1016\/j.tox.2025.154162_bib40","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jmb.2004.06.066","article-title":"NMR solution structure of an oxaliplatin 1,2-d(GG) intrastrand cross-link in a DNA dodecamer duplex","volume":"341","author":"Wu","year":"2004","journal-title":"J. Mol. Biol."},{"issue":"5243","key":"10.1016\/j.tox.2025.154162_bib41","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1126\/science.270.5243.1842","article-title":"Solution structure of a cisplatin-induced DNA interstrand cross-link","volume":"270","author":"Huang","year":"1995","journal-title":"Science"},{"issue":"38","key":"10.1016\/j.tox.2025.154162_bib42","doi-asserted-by":"crossref","first-page":"12305","DOI":"10.1021\/bi9904757","article-title":"Solution structure of a DNA duplex containing a cis-diammineplatinum(II) 1,3-d(GTG) intrastrand cross-link, a major adduct in cells treated with the anticancer drug carboplatin","volume":"38","author":"Teuben","year":"1999","journal-title":"Biochemistry"},{"issue":"4 Pt 2","key":"10.1016\/j.tox.2025.154162_bib43","first-page":"1972","article-title":"Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA","volume":"46","author":"Knox","year":"1986","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.tox.2025.154162_bib44","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1124\/mol.54.5.770","article-title":"Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA","volume":"54","author":"Woynarowski","year":"1998","journal-title":"Mol. Pharm."},{"issue":"1-2","key":"10.1016\/j.tox.2025.154162_bib45","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0009-2797(89)90061-6","article-title":"Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes","volume":"70","author":"Jennerwein","year":"1989","journal-title":"Chem. Biol. Inter."},{"issue":"4","key":"10.1016\/j.tox.2025.154162_bib46","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1021\/bi00456a026","article-title":"Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality","volume":"29","author":"Page","year":"1990","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.tox.2025.154162_bib47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.critrevonc.2004.08.008","article-title":"Recognition and processing of cisplatin- and oxaliplatin-DNA adducts","volume":"53","author":"Chaney","year":"2005","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.tox.2025.154162_bib48","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd1691","article-title":"Cellular processing of platinum anticancer drugs","volume":"4","author":"Wang","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tox.2025.154162_bib49","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1289\/ehp.9399149","article-title":"Platinum drug-DNA interactions in human tissues measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy","volume":"99","author":"Poirier","year":"1993","journal-title":"Environ. Health Perspect."},{"issue":"3","key":"10.1016\/j.tox.2025.154162_bib50","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002800050482","article-title":"The formation and persistence of carboplatin-DNA adducts in rats","volume":"38","author":"Blommaert","year":"1996","journal-title":"Cancer Chemother. Pharm."},{"issue":"1","key":"10.1016\/j.tox.2025.154162_bib51","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41467-019-08290-2","article-title":"Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs","volume":"10","author":"Yimit","year":"2019","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.tox.2025.154162_bib52","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1073\/pnas.94.2.514","article-title":"Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress","volume":"94","author":"Yakes","year":"1997","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.tox.2025.154162_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.669379","article-title":"The mitochondrial response to DNA damage","volume":"9","author":"Rong","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"1-2","key":"10.1016\/j.tox.2025.154162_bib54","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0165-1218(97)00037-2","article-title":"Preferential formation and decreased removal of cisplatin-DNA adducts in Chinese hamster ovary cell mitochondrial DNA as compared to nuclear DNA","volume":"391","author":"Olivero","year":"1997","journal-title":"Mutat. Res."},{"issue":"5","key":"10.1016\/j.tox.2025.154162_bib55","first-page":"949","article-title":"Preferential binding of cisplatin to mitochondrial DNA and suppression of ATP generation in human malignant melanoma cells","volume":"20","author":"Murata","year":"1990","journal-title":"Biochem. Int."},{"issue":"1","key":"10.1016\/j.tox.2025.154162_bib56","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1042\/BJ20071615","article-title":"Cisplatin-mediated impairment of mitochondrial DNA metabolism inversely correlates with glutathione levels","volume":"414","author":"Garrido","year":"2008","journal-title":"Biochem. J."},{"issue":"7","key":"10.1016\/j.tox.2025.154162_bib57","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.ajem.2010.07.005","article-title":"Carboplatin: a new cause of severe type B lactic acidosis secondary to mitochondrial DNA damage","volume":"29","author":"Brivet","year":"2011","journal-title":"Am. J. Emerg. Med."},{"issue":"5","key":"10.1016\/j.tox.2025.154162_bib58","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3109\/0886022X.2011.577546","article-title":"Effect of curcumin on cisplatin- and oxaliplatin-induced oxidative stress in human embryonic kidney (HEK) 293 cells","volume":"33","author":"Waly","year":"2011","journal-title":"Ren. Fail."},{"issue":"3","key":"10.1016\/j.tox.2025.154162_bib59","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.bbamcr.2014.12.033","article-title":"Platinum-induced kidney damage: Unraveling the DNA damage response (DDR) of renal tubular epithelial and glomerular endothelial cells following platinum injury","volume":"1853","author":"Kruger","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"issue":"9","key":"10.1016\/j.tox.2025.154162_bib60","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a012716","article-title":"DNA damage sensing by the ATM and ATR kinases","volume":"5","author":"Marechal","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"11","key":"10.1016\/j.tox.2025.154162_bib61","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1172\/JCI122313","article-title":"Proximal tubule ATR regulates DNA repair to prevent maladaptive renal injury responses","volume":"129","author":"Kishi","year":"2019","journal-title":"J. Clin. Invest"},{"issue":"10","key":"10.1016\/j.tox.2025.154162_bib62","doi-asserted-by":"crossref","first-page":"6572","DOI":"10.1074\/jbc.M707568200","article-title":"ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis","volume":"283","author":"Pabla","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.tox.2025.154162_bib63","doi-asserted-by":"crossref","first-page":"F1300","DOI":"10.1152\/ajprenal.00509.2005","article-title":"Caspase-mediated cleavage of ATM during cisplatin-induced tubular cell apoptosis: inactivation of its kinase activity toward p53","volume":"291","author":"Wang","year":"2006","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"9","key":"10.1016\/j.tox.2025.154162_bib64","doi-asserted-by":"crossref","first-page":"6076","DOI":"10.1128\/MCB.19.9.6076","article-title":"Cleavage and inactivation of ATM during apoptosis","volume":"19","author":"Smith","year":"1999","journal-title":"Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.tox.2025.154162_bib65","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1124\/jpet.302.1.8","article-title":"Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways","volume":"302","author":"Cummings","year":"2002","journal-title":"J. Pharm. Exp. Ther."},{"issue":"4","key":"10.1016\/j.tox.2025.154162_bib66","doi-asserted-by":"crossref","first-page":"F1282","DOI":"10.1152\/ajprenal.00230.2007","article-title":"Activation and involvement of p53 in cisplatin-induced nephrotoxicity","volume":"293","author":"Wei","year":"2007","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"11","key":"10.1016\/j.tox.2025.154162_bib67","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/nbt.3392","article-title":"Nephron organoids derived from human pluripotent stem cells model kidney development and injury","volume":"33","author":"Morizane","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"7","key":"10.1016\/j.tox.2025.154162_bib68","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00204-006-0173-2","article-title":"Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria","volume":"81","author":"Santos","year":"2007","journal-title":"Arch. Toxicol."},{"issue":"11","key":"10.1016\/j.tox.2025.154162_bib69","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/toxins2112490","article-title":"Mechanisms of Cisplatin nephrotoxicity","volume":"2","author":"Miller","year":"2010","journal-title":"Toxins"},{"issue":"12","key":"10.1016\/j.tox.2025.154162_bib70","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1038\/s41401-021-00620-9","article-title":"Natural products: potential treatments for cisplatin-induced nephrotoxicity","volume":"42","author":"Fang","year":"2021","journal-title":"Acta Pharm. Sin."},{"issue":"1","key":"10.1016\/j.tox.2025.154162_bib71","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10863-006-9001-x","article-title":"Preferential energy- and potential-dependent accumulation of cisplatin-gutathione complexes in human cancer cell lines (GLC4 and K562): a likely role of mitochondria","volume":"38","author":"Dzamitika","year":"2006","journal-title":"J. Bioenerg. Biomembr."},{"issue":"1","key":"10.1016\/j.tox.2025.154162_bib72","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10863-006-9059-5","article-title":"Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer","volume":"39","author":"Cullen","year":"2007","journal-title":"J. Bioenerg. Biomembr."},{"key":"10.1016\/j.tox.2025.154162_bib73","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.redox.2018.09.020","article-title":"Persistent increase in mitochondrial superoxide mediates cisplatin-induced chronic kidney disease","volume":"20","author":"Mapuskar","year":"2019","journal-title":"Redox Biol."},{"issue":"8","key":"10.1016\/j.tox.2025.154162_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135083","article-title":"Mechanism of cisplatin-induced cytotoxicity is correlated to impaired metabolism due to mitochondrial ROS generation","volume":"10","author":"Choi","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.tox.2025.154162_bib75","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S0022-3565(24)36493-6","article-title":"Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain","volume":"280","author":"Kruidering","year":"1997","journal-title":"J. Pharm. Exp. Ther."},{"issue":"1","key":"10.1016\/j.tox.2025.154162_bib76","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12929-019-0518-9","article-title":"Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity","volume":"26","author":"Volarevic","year":"2019","journal-title":"J. Biomed. Sci."},{"issue":"1-2","key":"10.1016\/j.tox.2025.154162_bib77","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1023\/A:1006889427520","article-title":"Protection by ebselen against cisplatin-induced nephrotoxicity: antioxidant system","volume":"178","author":"Husain","year":"1998","journal-title":"Mol. Cell Biochem"},{"issue":"1-2","key":"10.1016\/j.tox.2025.154162_bib78","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0300-2977(00)00081-4","article-title":"Dose response of carboplatin-induced hearing loss in rats: antioxidant defense system","volume":"151","author":"Husain","year":"2001","journal-title":"Hear Res."},{"issue":"6","key":"10.1016\/j.tox.2025.154162_bib79","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv394","article-title":"Role of reactive oxygen species in the abrogation of oxaliplatin activity by cetuximab in colorectal cancer","volume":"108","author":"Santoro","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.tox.2025.154162_bib80","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12951-022-01754-6","article-title":"Protective effect of spore oil-functionalized nano-selenium system on cisplatin-induced nephrotoxicity by regulating oxidative stress-mediated pathways and activating immune response","volume":"21","author":"Liu","year":"2023","journal-title":"J. Nanobiotechnology"},{"issue":"17","key":"10.1016\/j.tox.2025.154162_bib81","doi-asserted-by":"crossref","first-page":"13045","DOI":"10.1074\/jbc.M109.067728","article-title":"Kidney-specific overexpression of Sirt1 protects against acute kidney injury by retaining peroxisome function","volume":"285","author":"Hasegawa","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.tox.2025.154162_bib82","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1089\/ars.2012.5149","article-title":"Reactive oxygen species in inflammation and tissue injury","volume":"20","author":"Mittal","year":"2014","journal-title":"Antioxid. Redox Signal"},{"issue":"3","key":"10.1016\/j.tox.2025.154162_bib83","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/08860220601166487","article-title":"Effects of different doses of hyperbaric oxygen on cisplatin-induced nephrotoxicity","volume":"29","author":"Aydinoz","year":"2007","journal-title":"Ren. Fail."},{"key":"10.1016\/j.tox.2025.154162_bib84","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1749-6632.1993.tb18323.x","article-title":"Glutathione disulfide (GSSG) as a marker of oxidative injury to brain mitochondria","volume":"679","author":"Werner","year":"1993","journal-title":"Ann. N. Y Acad. Sci."},{"issue":"6","key":"10.1016\/j.tox.2025.154162_bib85","first-page":"7131","article-title":"Oxidative stress induced by carboplatin promotes apoptosis and inhibits migration of HN-3 cells","volume":"16","author":"He","year":"2018","journal-title":"Oncol. Lett."},{"issue":"2","key":"10.1016\/j.tox.2025.154162_bib86","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1124\/jpet.103.059410","article-title":"Kinetic study on the reactions of platinum drugs with glutathione","volume":"308","author":"Hagrman","year":"2004","journal-title":"J. Pharm. Exp. Ther."},{"issue":"3","key":"10.1016\/j.tox.2025.154162_bib87","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.phrs.2004.04.001","article-title":"Time response of carboplatin-induced nephrotoxicity in rats","volume":"50","author":"Husain","year":"2004","journal-title":"Pharm. Res."},{"issue":"5","key":"10.1016\/j.tox.2025.154162_bib88","first-page":"1295","article-title":"Exogenous glutathione contributes to cisplatin resistance in lung cancer A549 cells","volume":"10","author":"Lan","year":"2018","journal-title":"Am. J. Transl. Res."},{"issue":"5","key":"10.1016\/j.tox.2025.154162_bib89","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1046\/j.1523-1755.1998.00161.x","article-title":"Role of cytochrome P-450 as a source of catalytic iron in cisplatin-induced nephrotoxicity","volume":"54","author":"Baliga","year":"1998","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.tox.2025.154162_bib90","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1046\/j.1523-1755.2003.00908.x","article-title":"Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis","volume":"63","author":"Liu","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.tox.2025.154162_bib91","series-title":"Acute Renal Tubular Necrosis","author":"Hanif","year":"2022"},{"issue":"4 Pt 2","key":"10.1016\/j.tox.2025.154162_bib92","first-page":"F700","article-title":"Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis","volume":"270","author":"Lieberthal","year":"1996","journal-title":"Am. J. Physiol."},{"issue":"11","key":"10.1016\/j.tox.2025.154162_bib93","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1681\/ASN.2014080741","article-title":"A role for tubular necroptosis in cisplatin-induced AKI","volume":"26","author":"Xu","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.tox.2025.154162_bib94","doi-asserted-by":"crossref","first-page":"F610","DOI":"10.1152\/ajprenal.00101.2003","article-title":"TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure","volume":"285","author":"Ramesh","year":"2003","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"1","key":"10.1016\/j.tox.2025.154162_bib95","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/toxsci\/kfr098","article-title":"Necrotic concentrations of cisplatin activate the apoptotic machinery but inhibit effector caspases and interfere with the execution of apoptosis","volume":"122","author":"Sancho-Martinez","year":"2011","journal-title":"Toxicol. Sci."},{"issue":"22","key":"10.1016\/j.tox.2025.154162_bib96","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJM199605303342207","article-title":"Acute renal failure","volume":"334","author":"Thadhani","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.tox.2025.154162_bib97","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.kint.2018.11.042","article-title":"Regulated necrosis and failed repair in cisplatin-induced chronic kidney disease","volume":"95","author":"Landau","year":"2019","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.tox.2025.154162_bib98","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1046\/j.1523-1755.1998.00767.x","article-title":"In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity","volume":"53","author":"Baliga","year":"1998","journal-title":"Kidney Int."},{"key":"10.1016\/j.tox.2025.154162_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtemb.2021.126798","article-title":"Role of ferroptosis in cisplatin-induced acute nephrotoxicity in mice","volume":"67","author":"Ikeda","year":"2021","journal-title":"J. Trace Elem. Med. Biol."},{"issue":"1","key":"10.1016\/j.tox.2025.154162_bib100","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.ki.5002256","article-title":"The pathological role of Bax in cisplatin nephrotoxicity","volume":"72","author":"Wei","year":"2007","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.tox.2025.154162_bib101","first-page":"985","article-title":"Bcl-2 overexpression reduces cisplatin cytotoxicity by decreasing ER-mitochondrial Ca2+\u2009signaling in SKOV3 cells","volume":"39","author":"Xu","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.tox.2025.154162_bib102","first-page":"47","article-title":"Cisplatin nephrotoxicity: molecular mechanisms","volume":"1","author":"Hanigan","year":"2003","journal-title":"Cancer Ther."},{"issue":"16","key":"10.1016\/j.tox.2025.154162_bib103","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1042\/CS20170262","article-title":"TLR2 and TLR4 play opposite role in autophagy associated with cisplatin-induced acute kidney injury","volume":"132","author":"Andrade-Silva","year":"2018","journal-title":"Clin. Sci."},{"issue":"1","key":"10.1016\/j.tox.2025.154162_bib104","doi-asserted-by":"crossref","first-page":"F325","DOI":"10.1152\/ajprenal.00158.2007","article-title":"Endotoxin and cisplatin synergistically induce renal dysfunction and cytokine production in mice","volume":"293","author":"Ramesh","year":"2007","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"6","key":"10.1016\/j.tox.2025.154162_bib105","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1046\/j.1523-1755.2001.00043.x","article-title":"Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury","volume":"60","author":"Deng","year":"2001","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.tox.2025.154162_bib106","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1681\/ASN.2007090982","article-title":"TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity","volume":"19","author":"Zhang","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"issue":"12","key":"10.1016\/j.tox.2025.154162_bib107","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1681\/ASN.2011020182","article-title":"Mast cells mediate acute kidney injury through the production of TNF","volume":"22","author":"Summers","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.tox.2025.154162_bib108","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1172\/JCI200215606","article-title":"TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity","volume":"110","author":"Ramesh","year":"2002","journal-title":"J. Clin. Invest"},{"issue":"1","key":"10.1016\/j.tox.2025.154162_bib109","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/sj.ki.5002242","article-title":"Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells","volume":"72","author":"Zhang","year":"2007","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.tox.2025.154162_bib110","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1124\/jpet.107.119792","article-title":"Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney","volume":"322","author":"Faubel","year":"2007","journal-title":"J. Pharm. Exp. Ther."},{"issue":"3","key":"10.1016\/j.tox.2025.154162_bib111","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1681\/ASN.2005010102","article-title":"A pathophysiologic role for T lymphocytes in murine acute cisplatin nephrotoxicity","volume":"17","author":"Liu","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"issue":"8","key":"10.1016\/j.tox.2025.154162_bib112","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1093\/ndt\/gfl194","article-title":"Rosiglitazone ameliorates cisplatin-induced renal injury in mice","volume":"21","author":"Lee","year":"2006","journal-title":"Nephrol. Dial. Transpl."},{"key":"10.1016\/j.tox.2025.154162_bib113","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/967826","article-title":"Pathophysiology of cisplatin-induced acute kidney injury","volume":"2014","author":"Ozkok","year":"2014","journal-title":"Biomed. Res. Int."},{"issue":"8","key":"10.1016\/j.tox.2025.154162_bib114","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.3390\/toxins7083245","article-title":"Dendritic cell protection from cisplatin nephrotoxicity is independent of neutrophils","volume":"7","author":"Tadagavadi","year":"2015","journal-title":"Toxins"},{"issue":"9","key":"10.1016\/j.tox.2025.154162_bib115","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.freeradbiomed.2011.08.006","article-title":"Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury","volume":"51","author":"Mukhopadhyay","year":"2011","journal-title":"Free Radic. Biol. Med."},{"issue":"3","key":"10.1016\/j.tox.2025.154162_bib116","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/0002-9343(91)80022-E","article-title":"Acute renal failure associated with the use of intraperitoneal carboplatin: a report of two cases and review of the literature","volume":"90","author":"McDonald","year":"1991","journal-title":"Am. J. Med."},{"issue":"8","key":"10.1016\/j.tox.2025.154162_bib117","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1080\/08860220701643591","article-title":"End-stage renal disease following carboplatin chemotherapy for a nasopharyngeal carcinoma","volume":"29","author":"Tarrass","year":"2007","journal-title":"Ren. Fail."},{"issue":"1","key":"10.1016\/j.tox.2025.154162_bib118","first-page":"1","article-title":"Acute toxicologic and pathologic effects of cis-diamminedichloroplatinum (NSC-119875) in the male rat","volume":"55","author":"Kociba","year":"1971","journal-title":"Cancer Chemother. Rep."},{"issue":"3","key":"10.1016\/j.tox.2025.154162_bib119","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1681\/ASN.2014090927","article-title":"Endogenous toll-like receptor 9 regulates AKI by promoting regulatory T Cell Recruitment","volume":"27","author":"Alikhan","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"issue":"12","key":"10.1016\/j.tox.2025.154162_bib120","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/annonc\/mdf311","article-title":"A case of acute tubular necrosis due to oxaliplatin","volume":"13","author":"Pinotti","year":"2002","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.tox.2025.154162_bib121","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s10157-004-0304-0","article-title":"Experimental study of renal disorder caused by oxaliplatin in rat renal cortical slices","volume":"8","author":"Kanou","year":"2004","journal-title":"Clin. Exp. Nephrol."},{"issue":"6","key":"10.1016\/j.tox.2025.154162_bib122","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/ndt\/gfh826","article-title":"Renal toxicity of oxaliplatin","volume":"20","author":"Labaye","year":"2005","journal-title":"Nephrol. Dial. Transpl."},{"issue":"9","key":"10.1016\/j.tox.2025.154162_bib123","first-page":"873","article-title":"Toxic effect of two antitumoral agents derived from platinum, the cisplatin and the oxaliplatin on primary cultures of proximal tubular cells of the kidney in rabbits","volume":"41","author":"Legallicier","year":"1993","journal-title":"Pathol. Biol."},{"issue":"8","key":"10.1016\/j.tox.2025.154162_bib124","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9081033","article-title":"In vitro nephrotoxicity studies of established and experimental platinum-based compounds","volume":"9","author":"Schoch","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.tox.2025.154162_bib125","first-page":"81","article-title":"In vitro effects of platinum compounds on renal cellular respiration in mice","volume":"8","author":"Almarzooqi","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"9","key":"10.1016\/j.tox.2025.154162_bib126","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s11095-010-0189-4","article-title":"Pharmacokinetics and toxicodynamics of oxaliplatin in rats: application of a toxicity factor to explain differences in the nephrotoxicity and myelosuppression induced by oxaliplatin and the other platinum antitumor derivatives","volume":"27","author":"Hanada","year":"2010","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.tox.2025.154162_bib127","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/gyno.1993.1184","article-title":"Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin","volume":"50","author":"Cornelison","year":"1993","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.tox.2025.154162_bib128","doi-asserted-by":"crossref","first-page":"1462802","DOI":"10.1155\/2018\/1462802","article-title":"Cisplatin-induced rodent model of kidney injury: characteristics and challenges","volume":"2018","author":"Perse","year":"2018","journal-title":"Biomed. Res. Int."},{"issue":"10","key":"10.1016\/j.tox.2025.154162_bib129","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1038\/s41588-024-01904-6","article-title":"Variants in tubule epithelial regulatory elements mediate most heritable differences in human kidney function","volume":"56","author":"Loeb","year":"2024","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.tox.2025.154162_bib130","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1158\/1078-0432.CCR-11-2503","article-title":"Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients","volume":"18","author":"Ciarimboli","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.tox.2025.154162_bib131","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.semnephrol.2010.09.005","article-title":"Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention\/therapy","volume":"30","author":"Perazella","year":"2010","journal-title":"Semin Nephrol."},{"issue":"5","key":"10.1016\/j.tox.2025.154162_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/S0272-6386(98)70152-0","article-title":"Carboplatin-related hematuria and acute renal failure","volume":"32","author":"Agraharkar","year":"1998","journal-title":"Am. J. Kidney Dis."},{"issue":"3","key":"10.1016\/j.tox.2025.154162_bib133","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/CAD.0b013e3280102f4b","article-title":"Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: a case report","volume":"18","author":"Buti","year":"2007","journal-title":"Anticancer Drugs"},{"issue":"4","key":"10.1016\/j.tox.2025.154162_bib134","first-page":"283","article-title":"Oxaliplatin induces a delayed immune-mediated hemolytic anemia: a case report and review of the literature","volume":"5","author":"Noronha","year":"2005","journal-title":"Clin. Colorectal Cancer"},{"issue":"4","key":"10.1016\/j.tox.2025.154162_bib135","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s12032-009-9263-3","article-title":"Acute renal failure related to oxaliplatin-induced intravascular hemolysis","volume":"27","author":"Ulusakarya","year":"2010","journal-title":"Med. Oncol."},{"issue":"6","key":"10.1016\/j.tox.2025.154162_bib136","doi-asserted-by":"crossref","first-page":"F1140","DOI":"10.1152\/ajprenal.00262.2004","article-title":"Role of p53 in cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity","volume":"287","author":"Jiang","year":"2004","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"1","key":"10.1016\/j.tox.2025.154162_bib137","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1046\/j.1523-1755.2003.00709.x","article-title":"Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death","volume":"63","author":"Tsuruya","year":"2003","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.tox.2025.154162_bib138","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1074\/jbc.M606928200","article-title":"Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax\/Bak activation","volume":"282","author":"Jiang","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"1-2","key":"10.1016\/j.tox.2025.154162_bib139","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0009-2797(89)90065-3","article-title":"Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug","volume":"70","author":"Zunino","year":"1989","journal-title":"Chem. Biol. Inter."},{"issue":"1-2","key":"10.1016\/j.tox.2025.154162_bib140","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.heares.2004.08.002","article-title":"Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen","volume":"201","author":"Lynch","year":"2005","journal-title":"Hear Res."},{"issue":"2","key":"10.1016\/j.tox.2025.154162_bib141","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.bbadis.2005.10.007","article-title":"Targeting antioxidants to mitochondria: a new therapeutic direction","volume":"1762","author":"Sheu","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.tox.2025.154162_bib142","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1523-1755.2004.00413.x","article-title":"Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-alpha","volume":"65","author":"Ramesh","year":"2004","journal-title":"Kidney Int."},{"issue":"8","key":"10.1016\/j.tox.2025.154162_bib143","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26082382","article-title":"Elucidating role of reactive oxygen species (ROS) in cisplatin chemotherapy: a focus on molecular pathways and possible therapeutic strategies","volume":"26","author":"Mirzaei","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.tox.2025.154162_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.120071","article-title":"Punicalagin prevents cisplatin-induced nephrotoxicity by attenuating oxidative stress, inflammatory response, and apoptosis in rats","volume":"286","author":"Aladaileh","year":"2021","journal-title":"Life Sci."},{"issue":"6","key":"10.1016\/j.tox.2025.154162_bib145","doi-asserted-by":"crossref","first-page":"C1466","DOI":"10.1152\/ajpcell.00265.2005","article-title":"Mitochondrial density determines the cellular sensitivity to cisplatin-induced cell death","volume":"289","author":"Qian","year":"2005","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"4","key":"10.1016\/j.tox.2025.154162_bib146","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1124\/mol.59.4.657","article-title":"Is cisplatin-induced cell death always produced by apoptosis?","volume":"59","author":"Gonzalez","year":"2001","journal-title":"Mol. Pharm."},{"issue":"12","key":"10.1016\/j.tox.2025.154162_bib147","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/bjc.1996.296","article-title":"Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours","volume":"73","author":"Schellens","year":"1996","journal-title":"Br. J. Cancer"},{"issue":"1-2","key":"10.1016\/j.tox.2025.154162_bib148","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF00685625","article-title":"Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts","volume":"37","author":"Johnsson","year":"1995","journal-title":"Cancer Chemother. Pharm."},{"issue":"1","key":"10.1016\/j.tox.2025.154162_bib149","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/sj.bjc.6690015","article-title":"Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo","volume":"79","author":"Welters","year":"1999","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.tox.2025.154162_bib150","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/sj.ki.5002786","article-title":"Cisplatin nephrotoxicity: mechanisms and renoprotective strategies","volume":"73","author":"Pabla","year":"2008","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.tox.2025.154162_bib151","doi-asserted-by":"crossref","first-page":"20920","DOI":"10.1038\/s41598-021-00392-6","article-title":"Cumulative DNA damage by repeated low-dose cisplatin injection promotes the transition of acute to chronic kidney injury in mice","volume":"11","author":"Yamashita","year":"2021","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.tox.2025.154162_bib152","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41374-018-0063-2","article-title":"Cisplatin nephrotoxicity as a model of chronic kidney disease","volume":"98","author":"Shi","year":"2018","journal-title":"Lab Invest"},{"key":"10.1016\/j.tox.2025.154162_bib153","series-title":"Users\u2019 Handbook Supplement to the Guidance Document for Developing and Assessing Adverse Outcome Pathways","author":"OECD","year":"2018"}],"container-title":["Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X25001192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X25001192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T11:19:07Z","timestamp":1769858347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300483X25001192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":153,"alternative-id":["S0300483X25001192"],"URL":"https:\/\/doi.org\/10.1016\/j.tox.2025.154162","relation":{},"ISSN":["0300-483X"],"issn-type":[{"value":"0300-483X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An adverse outcome pathway for DNA adduct formation leading to kidney failure","name":"articletitle","label":"Article Title"},{"value":"Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tox.2025.154162","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"154162"}}